FDA Expands Approval for J&J's Rare Blood Disorder Drug
JNJ sits 58% above its 52-week low of $173.33.
Summary
The FDA approved an expanded indication for Johnson & Johnson's drug IMAAVY (nipocalimab-aahu) as the first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), a rare, life-threatening autoantibody disease in adults and pediatric patients 12 years of age and older. This is a new regulatory milestone that broadens the drug's addressable patient population and reinforces J&J's pipeline momentum. The company has had a series of positive regulatory and clinical developments in recent months, including label expansions and strong trial data. The approval itself is a material positive for the pharmaceutical segment. Investors will look for details on the drug's commercial potential and any updated guidance in upcoming filings.
Updates
· Benzinga — Phase 2/3 ENERGY study showed about three times as many patients achieved durable hemoglobin response versus placebo, with mean Hgb increase of 1g/dL at Week 1 and 3.5-point higher fatigue score at Week 24. J&J shares down 0.33% premarket at $270.81.
At the time of this announcement, JNJ was trading at $273.38 on NYSE in the Life Sciences sector, with a market capitalization of approximately $658B. The 52-week trading range was $173.33 to $276.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.